机构:[1]Department of Gynecological Oncology, Tianjin Medical Cancer Instituteand Hospital, National Clinical Research Center for Cancer, Key Laboratoryof Cancer Prevention and Therapy,Tianjin, Tianjin’s Clinical Research Centerfor Cancer, West Huan‑Hu Rd, Ti Yuan Bei, Hexi District, 300060 Tianjin, China[2]Department of Internal Medicine, Second Affiliated College of HarbinMedical University, 246 Xuefu Road, Nangang District, Harbin City 230100,Heilongjiang Province, China[3]YuceBio Technology Co., Ltd, 4th floor, phaseI, dabaihui center, no.2002, Shenyan Road, Haishan street, Yantian District,Shenzhen City 440300, Guangdong Province, China[4]Department of Obstetricsand Gynecology, The Fourth Hospital of Hebei Medical University, NO.12,JianKang Road, Shijiazhuang 130100, Hebei Province, China临床科室产科河北医科大学第四医院
第一作者机构:[1]Department of Gynecological Oncology, Tianjin Medical Cancer Instituteand Hospital, National Clinical Research Center for Cancer, Key Laboratoryof Cancer Prevention and Therapy,Tianjin, Tianjin’s Clinical Research Centerfor Cancer, West Huan‑Hu Rd, Ti Yuan Bei, Hexi District, 300060 Tianjin, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Liu Wenxin,Jiang Qiuying,Sun Chao,et al.Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations.[J].BMC CANCER.2022,22(1):doi:10.1186/s12885-022-09291-z.
APA:
Liu Wenxin,Jiang Qiuying,Sun Chao,Liu ShiHao,Zhao Zhikun&Wu Dongfang.(2022).Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations..BMC CANCER,22,(1)
MLA:
Liu Wenxin,et al."Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations.".BMC CANCER 22..1(2022)